tiprankstipranks
Trending News
More News >
IDT Australia Limited (AU:IDT)
:IDT
Australian Market
Advertisement

IDT Australia Limited (IDT) AI Stock Analysis

Compare
4 Followers

Top Page

AU:IDT

IDT Australia Limited

(Sydney:IDT)

Rating:46Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
The overall stock score for IDT Australia Limited is primarily driven by its financial performance challenges, including persistent losses and negative cash flow. Technical analysis provides a slightly more favorable view, but valuation concerns due to negative earnings significantly impact the stock's attractiveness.

IDT Australia Limited (IDT) vs. iShares MSCI Australia ETF (EWA)

IDT Australia Limited Business Overview & Revenue Model

Company DescriptionIDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. It offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. The company also provides project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in various dosage forms. In addition, it offers medicinal cannabis products, as well as various contract manufacturing services. The company was founded in 1975 and is headquartered in Boronia, Australia.
How the Company Makes MoneyIDT Australia Limited generates revenue primarily through the manufacturing and sale of pharmaceutical products. The company produces active pharmaceutical ingredients (APIs) and finished dosage forms, which are sold to pharmaceutical companies, hospitals, and other healthcare providers. Additionally, IDT offers contract manufacturing services, leveraging its advanced production facilities to produce pharmaceuticals for third parties. The company may also engage in partnerships and collaborations with other pharmaceutical firms to enhance its product offerings and market reach, contributing to its revenue streams.

IDT Australia Limited Financial Statement Overview

Summary
IDT Australia Limited faces substantial financial hurdles, with persistent losses and negative cash flow. While revenue growth is a positive sign, the company needs to address operational inefficiencies and improve cash management. The low leverage provides some stability, but enhancing profitability is crucial for future growth.
Income Statement
45
Neutral
The income statement reveals a troubling trend in profitability. Despite revenue growth of 90.7% from 2023 to 2024, the company has consistently posted net losses, with a net profit margin of -40.9% in 2024. The gross profit margin improved to 50.7% in 2024, but negative EBIT and EBITDA margins suggest operational inefficiencies.
Balance Sheet
50
Neutral
The balance sheet shows a moderate level of risk. The debt-to-equity ratio is 0.19, indicating low leverage, which is positive. However, stockholders' equity has decreased over the years, and the equity ratio stands at 74.7%. The company's total assets have grown, but there's a need to improve equity growth to support long-term stability.
Cash Flow
40
Negative
Cash flow analysis indicates significant challenges. The free cash flow in 2024 was deeply negative, showing a decline from 2023. The operating cash flow to net income ratio is negative, highlighting cash flow generation issues relative to reported losses.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue13.23M6.93M12.11M15.99M14.10M
Gross Profit10.42M-3.53M10.66M4.88M3.37M
EBITDA-5.03M-8.83M-340.00K2.75M721.00K
Net Income-5.41M-8.50M-1.16M2.10M-1.92M
Balance Sheet
Total Assets31.37M28.29M30.08M34.13M28.59M
Cash, Cash Equivalents and Short-Term Investments904.00K4.43M9.21M6.93M6.86M
Total Debt4.47M740.00K881.00K766.00K5.00K
Total Liabilities7.93M4.15M3.46M6.51M5.29M
Stockholders Equity23.44M24.14M26.63M27.61M23.30M
Cash Flow
Free Cash Flow-10.30M-8.42M1.95M-156.00K-2.65M
Operating Cash Flow-9.60M-7.90M2.86M370.00K-1.89M
Investing Cash Flow-1.09M-522.00K-912.00K-526.00K-761.00K
Financing Cash Flow6.77M3.64M337.00K224.00K12.00K

IDT Australia Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.10
Price Trends
50DMA
0.10
Positive
100DMA
0.10
Positive
200DMA
0.10
Negative
Market Momentum
MACD
<0.01
Negative
RSI
53.36
Neutral
STOCH
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.36 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IDT.

IDT Australia Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
50
Neutral
AU$2.62B3.32-57.47%2.40%36.73%13.67%
46
Neutral
AU$40.03M-19.31%72.25%43.66%
$27.95M-130.18%
AU$33.53M10.004.10%
63
Neutral
AU$43.05M19.124.85%5.76%-79.76%
53
Neutral
AU$23.03M-218.38%-14.30%29.69%
41
Neutral
AU$74.35M-45.40%13.61%-55.12%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:IDT
IDT Australia Limited
0.10
-0.02
-16.67%
NXSCF
Next Science Ltd
0.10
-0.08
-44.44%
AU:LGP
Little Green Pharma Ltd.
0.11
<0.01
10.00%
AU:MVP
Medical Developments International Limited
0.65
0.18
38.30%
AU:AGH
Althea Group Holdings Ltd.
0.03
<0.01
50.00%
AU:VIT
Cronos Australia Ltd.
0.06
-0.03
-33.33%

IDT Australia Limited Corporate Events

IDT Australia Limited Announces Cessation of Securities
Jul 15, 2025

IDT Australia Limited announced the cessation of 861,000 ordinary fully paid securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for its market positioning and stakeholder interests.

IDT Australia Reports 30% Revenue Growth and Strong Contract Pipeline
Apr 29, 2025

IDT Australia Limited reported a 30% increase in quarterly revenue, reaching $4.1 million, driven by new contract wins and a strong pipeline of potential contracts totaling $62 million. The company experienced significant growth in its Active Pharmaceutical Ingredients vertical, which is expected to positively impact its Advanced Therapies and Specialty Orals segments. Despite global trade uncertainties, IDT’s outlook remains positive, with new contracts and proposals indicating robust future growth opportunities.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025